

NHCI 2025 SYMPOSIUM

**NORTHSIDE
HOSPITAL**
CANCER INSTITUTE
"BUILT TO BEAT **CANCER**"

Personalizing Cancer Treatment in the Era of Genomics and Precision Oncology



SATURDAY, MARCH 29, 2025
The Westin Buckhead Atlanta

AGENDA

7:00-8:00 a.m. Registration and Breakfast

8:00-8:05 a.m. Welcome
Paul Gill, MD

PLENARY 1

Multidisciplinary Approach to Genomic Oncology

Co-Chairs: TBD

8:05-8:30 a.m. The Evolving Role of Pathology in Genomic Oncology
Michelle Shiller, DO

8:30-8:55 a.m. Personalizing Anticancer Therapy Using Pharmacogenomics and Pharmacokinetics
Christine Walko, PharmD

8:55-9:20 a.m. Clinical Applications of ctDNA: Current and Future Perspective
Bruna Pellini, MD

9:20-9:35 a.m. Q&A

9:35-10:00 a.m. Break

PLENARY 2

Emerging Mutations and New Targeted Therapies

Co-Chairs: TBD

10:00-10:30 a.m. New Targeted Therapies for HR-Positive Breast Cancer
Erica Meyer, MD (TBD)

10:30-11:00 a.m. Precision Oncology to Guide Targeted Therapies for Lung Cancer
Jyoti Patel MD (TBD)

11:00-11:30 a.m. Prostate Cancer – Current and Emerging Paradigms of Biomarker-Guided Therapies
Neeraj Agarwal, MD

11:30-12:00 p.m. Targeted Therapies for Gastric and Gastroesophageal Junction Cancers
Alexandria T. Phan, MD

12:00-12:15 p.m. Q&A

12:15-1:00 p.m. Lunch

KEYNOTE ADDRESS

Co-Chair: Paul Gill, MD

1:00-1:45 p.m. Leveraging Technology and AI to Improve Precision Medicine in Community Oncology Practices
Maryellen Giger, PhD

PLENARY 3

Panel Discussion: Molecular Tumor Board

Co-Chairs: TBD

1:45-2:20 p.m. Treatment Decisions for Stage II and III NSCLC with Driver Mutations: Multidisciplinary Panel Presentation & Discussion
TBD

2:20-3:05 p.m. Breast Cancer Patient Case: Multidisciplinary Panel Presentation & Discussion
TBD

3:05-3:10 p.m. Closing Remarks

LEARNING OBJECTIVES:

Upon completion of this educational activity, participants should be able to:

1. Interpret results of next-generation sequencing and other biomarkers predictive of response to targeted therapies and recognize the challenges involved;
2. Plan optimal molecular-targeted treatment strategies for the treatment of cancer;
3. Explain the role, including advantages and disadvantages, of different testing methodologies available for a selection of targeted therapies;
4. Review the role and timing of diagnostic tests, molecular profiling, and potential combinations of targeted-therapy treatment options;
5. Summarize recent and emerging data from key studies in clinical and translational cancer research;
6. Describe common molecular alterations and the role of molecular diagnostic tests in different cancer types;
7. Summarize diagnostic and treatment-related data relevant to optimal multidisciplinary care; and
8. Assess the most relevant data on the current and evolving role of genomic assays in cancer management.